In the context of AML, DNMT3A manifests a notably high mutation frequency, which is closely intertwined with an unfavorable prognosis and resistance to therapeutic interventions.171 Abnormal expression of DNMT3A in tumors is usually characterized by upregulation, which is associated with enhanced abilities of tumor cells to proliferate, migrate, and invade. This evidence concerns the gene DNMT3A and acute myeloid leukemia.